Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 10  |  Issue : 2  |  Page : 279-283

Post-mastectomy radiation beyond chest wall in patients with N1 breast cancer: Is there a benefit?

Department of Radiation Oncology, Regional Cancer Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Budhi Singh Yadav
Department of Radiation Oncology, Regional Cancer Centre, Post Graduate Institute of Medical Education and Research, Chandigarh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.136560

Rights and Permissions

Introduction: Nodal stage is the most important prognostic factor and one of the indicators for loco-regional radiation in patients with breast cancer. N1 (patients with 1-3 lymph node metastases in axilla) nodal stage is a controversial area as far as axillary and supraclavicular fossa (SCF) irradiation is concerned. We conducted a retrospective analysis at our institute to assess the impact of post-mastectomy radiotherapy (PMRT) beyond chest wall (CW) in N1- nodal stage breast cancer patients. Materials and Methods: Since January 2004 to December 2007, 293 post-mastectomy patients with N1 nodal stage breast cancer were analyzed for patient-related characteristics such as age, menopausal status, pathological stage/tumour size, tumour location, histology, oestrogen/progesterone receptor status, histological grade, extra capsular extension, lymph vascular invasion and treatment-related factors, PMRT and systemic therapy. Outcome studied were locoregional recurrence rate (LRR), disease free survival (DFS) and overall survival (OS). Results: At a median follow up of 55m, 260 patients received radiotherapy; 212 to CW+SCF, 48 to the CW only; and 33 patients did not receive radiotherapy. LRR was 5% in patients who received radiotherapy to CW+SCF and 8% in CW only (P = 0.34). There was no difference in the DFS between the two groups. OS at 5 year was 88% in CW+SCF group and 76% in CW only group respectively (P < 0.001). Conclusion: In N1 nodal stage patients with breast cancer LRR was not significantly different after radiation to CW+SCF or to the CW only but OS was significantly better.

Abstract in Chinese

N1乳腺癌患者行扩大胸壁范围的术后放疗是否有获益? 摘要 背景:淋巴结分期是影响预后的重要因素之一,也是乳腺癌患者的局部区域放疗的指征。N1(1到3个淋巴结转移的腋窝淋巴结分期患者)的腋窝和锁骨上窝(SCF)照射是一个有争议的地区。我们对在我院术后放疗(PMRT)的范围超过胸壁(CW)的N1淋巴结分期的乳腺癌患者进行了一项回顾性分析。 材料与方法:自2004年1月至2007年12月共293术后患者N1淋巴结分期的乳腺癌患者,分析临床病理因素如年龄,绝经状态,病理分期/肿瘤的大小,肿瘤位置,组织学,雌激素/孕激素受体状态,组织学分级,包膜外侵犯,淋巴血管侵犯,术后放疗和全身治疗等与预后的关系。研究结果为局部复发率(LRR),无病生存率(DFS)和总生存期(OS)。 结果:平均随访55个月,260例病人接受了放疗:212例 CW + SCF(胸壁+锁骨上窝),48例只进行胸壁放疗。另外33例未接受放疗。局部复发率LRR :胸壁+锁骨上窝组为5%,单纯胸壁组 8%(P = 0.34)。两组之间在DFS无显着差异。5年生存率为88%(胸壁+锁骨上窝组)和 76%(单纯胸壁组)(P<0.001)。 结论:胸壁+锁骨上窝照射较单纯胸壁放疗在N1淋巴结分期乳腺癌患者中的局部复发率无显著差异,但前者 OS明显高于后者。 关键词:乳腺癌,胸壁,局部复发率,总生存率,术后放疗

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded159    
    Comments [Add]    

Recommend this journal